Opthea (NASDAQ:OPT) PT Lowered to $12.00

Opthea (NASDAQ:OPT) had its target price reduced by HC Wainwright from $14.00 to $12.00 in a report published on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Opthea’s FY2029 earnings at $0.50 EPS.

Opthea Trading Up 3.1 %

OPT opened at $2.98 on Tuesday. The business’s 50-day simple moving average is $2.35 and its 200 day simple moving average is $2.93. Opthea has a 52-week low of $1.60 and a 52-week high of $4.40.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.